Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FROM TRIAL: In adults with acquired TTP, cap...
| Hoofdauteur: | |
|---|---|
| Formaat: | Journal article |
| Taal: | English |
| Gepubliceerd in: |
Wiley
2019
|
| _version_ | 1826257110705373184 |
|---|---|
| author | Estcourt, L |
| author_facet | Estcourt, L |
| author_sort | Estcourt, L |
| collection | OXFORD |
| description | CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FROM TRIAL: In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP-related death and recurrence of TTP. |
| first_indexed | 2024-03-06T18:12:56Z |
| format | Journal article |
| id | oxford-uuid:03a2bd66-ab74-448b-98ee-99ab409bfd07 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:12:56Z |
| publishDate | 2019 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:03a2bd66-ab74-448b-98ee-99ab409bfd072022-03-26T08:47:24ZCaplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:03a2bd66-ab74-448b-98ee-99ab409bfd07EnglishSymplectic Elements at OxfordWiley2019Estcourt, LCLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FROM TRIAL: In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP-related death and recurrence of TTP. |
| spellingShingle | Estcourt, L Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial) |
| title | Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial) |
| title_full | Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial) |
| title_fullStr | Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial) |
| title_full_unstemmed | Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial) |
| title_short | Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial) |
| title_sort | caplacizumab treatment for acquired thrombotic thrombocytopenic purpura hercules trial |
| work_keys_str_mv | AT estcourtl caplacizumabtreatmentforacquiredthromboticthrombocytopenicpurpuraherculestrial |